Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, single-arm, investigator-initiated clinical study designed to evaluate the safety and efficacy of lenalidomide in combination with targeted therapy and immunotherapy in patients with advanced hepatocellular carcinoma (HCC) who have experienced disease progression after multiple lines of systemic treatment. Eligible patients must have received at least two prior lines of systemic therapy, including both targeted therapy and immune checkpoint inhibitor (ICI)-based treatment, and must have previously achieved clinical benefit from their most recent treatment regimen before developing disease progression. Participants will continue their current targeted therapy and immunotherapy regimen and receive lenalidomide as add-on treatment. The study will assess antitumor activity, survival outcomes, and treatment-related adverse events. The primary objectives are to evaluate 6-month progression-free survival (PFS) and the incidence of grade ≥3 treatment-related adverse events (TRAEs). Secondary objectives include objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and overall survival (OS).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony diagnozą rak wątroby
- •Rak wątroby niemożliwy do operacji lub rozprzestrzeniający się
- •Co najmniej dwa poprzednie leczenia systemowe (terapia celowana i immunoterapia)
- •Ostatnie leczenie pomagało (całkowita lub częściowa odpowiedź albo zatrzymanie choroby przez co najmniej 4 tygodnie)
- •Co najmniej jeden zmierzalny guz
- •Dobra ogólna sprawność fizyczna (0-1 w skali ECOG)
- •Prawidłowe parametry krwi i funkcji narządów
✗ Disqualifies
- •Szybki wzrost nowotworu bez odpowiedzi na ostatnie leczenie (w ciągu 6 tygodni)
- •Wcześniejsze leczenie lenalidomidem lub ciężka alergiczna reaction na lenalidomid czy talidomid
- •Bardzo szybkie pogorszenie stanu, kiedy kontynuacja leczenia jest nieuzasadniona
- •Niekontrolowana płynność w brzuchu, encefalopatia wątrobowa lub krwawienie z przewodu pokarmowego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Peking Union Medical College Hospital
Beijing, China
Trial contact
Jiayue Li
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.